LGND Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ligand Pharmaceuticals Inc (LGND) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and promising catalysts make it a solid investment opportunity.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 71.609, and moving averages are converging, suggesting a potential continuation of the current trend. The stock is trading near resistance levels (R1: 196.145), which could indicate a breakout opportunity.
Strong Q4 2025 financial performance with a 60% YoY revenue increase and adjusted EPS exceeding guidance by 30%.
Positive Phase 3 SELVA trial results for QTORIN, increasing its odds of success to 90% and peak sales projection to $1B.
Analysts have raised price targets and maintained Buy ratings, with a high target of $
Reaffirmed 2026 financial guidance with strong EPS projections between $8.00 and $9.00.
Post-market price dropped by -1.94%, which may indicate short-term selling pressure.
No significant hedge fund or insider trading trends to support strong institutional confidence.
Ligand Pharmaceuticals reported Q4 2025 revenues of $59.7 million, a 39% increase YoY, and adjusted net income of $42.7 million. The company also achieved a 60% YoY revenue increase for the full year and exceeded EPS guidance by over 30%. Gross margin improved to 89.7%, up 13.07% YoY.
Analysts are highly positive on LGND. H.C. Wainwright raised the price target to $239, citing strong trial results and increased sales projections. Stifel raised the target to $230, highlighting key growth drivers. Citi initiated coverage with a Buy rating and a $270 target, emphasizing the company's focus on royalties and platform out-licensing, which reduces volatility and concentration risk.
